...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
【24h】

Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.

机译:术前放化疗治疗食道癌可能会增加手术死亡率。

获取原文
获取原文并翻译 | 示例

摘要

AIMS: This phase II multicentric study evaluates a modified preoperative chemoradiotherapy schedule.METHODS: Patients <75 years with potentially resectable neoplasm were eligible. Treatment included an initial course of CDDP 100 mg/m(2) (Day 1) and 5-FU CI 5000 mg/m(2) (Days 1-5) followed by 45Gy (Days 28-63) and 5-FU CI 5000 mg/m(2) (Days 28-33), CDDP 75 mg/m(2) (Day 56) and 5-FU CI 3750 mg/m(2) (Days 56-61). Regional lymph nodes were irradiated.RESULTS: Nineteen patients were studied. Oesophagectomy was performed in 17. Clear margins were achieved in 16 of these. Eight patients showed a pathologic complete response (pCR). One patient died of infection during the preoperative treatment and four died due to acute surgical complications. The study was closed prematurely because of excessive mortality. Median follow-up was 19 months. Local and regional relapse occurred in one and three patients, respectively. Median time and actuarial 3-year of overall survival and progression free rates were 18.6 monthsand 28%, and 12.7 months and 10.4%, respectively.CONCLUSIONS: This schedule showed a high pCR, resectability and local control rate. Treatment-related mortality limits its clinical applicability, but further investigations are warranted.
机译:目的:该II期多中心研究评估了改良的术前放化疗方案。方法:年龄<75岁且有可能切除的肿瘤的患者符合条件。治疗包括CDDP的初始疗程100 mg / m(2)(第1天)和5-FU CI 5000 mg / m(2)(1-5天),然后是45Gy(28-63天)和5-FU CI 5000 mg / m(2)(第28-33天),CDDP 75 mg / m(2)(第56天)和5-FU CI 3750 mg / m(2)(第56-61天)。结果:对19例患者进行了研究。食道切除术在17例中进行。八名患者表现出病理完全缓解(pCR)。一名患者在术前治疗中死于感染,四名由于急性手术并发症而死亡。由于死亡率过高,该研究提早结束。中位随访时间为19个月。一例和三例患者分别发生局部和区域复发。结论:该时间表显示较高的pCR,可切除性和局部控制率,中位时间和精算3年总生存率和无进展率分别为18.6个月和28%,12.7个月和10.4%。与治疗有关的死亡率限制了其临床适用性,但是有必要进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号